Key Findings:
- Suppressed KLK2 expression was observed in a cohort of prostate cancer patients treated with ADT±androgen receptor pathway inhibitor (ARPI), potentially supporting KLK2’s androgen-regulated role in prostate cancer.
- Tumors with high KLK2 expression were enriched with immunosuppressive cells and had fewer pro-inflammatory immune cells, suggesting an immunosuppressive tumor microenvironment.
- These findings highlight KLK2 as a potential biomarker and therapeutic target in prostate cancer, warranting further validation.